A step towards treating KRAS-mutant NSCLC

被引：8
|
作者：
Goldberg, Sarah B. [1 ,2 ]
Schlessinger, Joseph [1 ,3 ]
Boyer, Julie L. [1 ,2 ]
Herbst, Roy S. [1 ,2 ,3 ]
机构：
[1] Yale Univ, Sch Med, Yale Comprehens Canc Ctr, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Internal Med, Sect Med Oncol, New Haven, CT 06520 USA
[3] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA
来源：
LANCET ONCOLOGY | 2013年 / 14卷 / 01期
关键词：
CELL LUNG-CANCER; DOCETAXEL; TRIAL;
D O I：
10.1016/S1470-2045(12)70528-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3 / 5
页数：4
相关论文
共 50 条
  • [1] Treating KRAS-mutant NSCLC: latest evidence and clinical consequences
    Garrido, Pilar
    Eugenia Olmedo, Maria
    Gomez, Ana
    Paz Ares, Luis
    Lopez-Rios, Fernando
    Manuel Rosa-Rosa, Juan
    Palacios, Jose
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2017, 9 (09) : 589 - 597
  • [2] Sotorasib effective in KRAS-mutant NSCLC
    Sidaway, Peter
    NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (08) : 470 - 470
  • [3] Novel agents for KRAS-mutant NSCLC
    Janne, Pasi A.
    ANNALS OF ONCOLOGY, 2022, 33 : S444 - S444
  • [4] Sotorasib effective in KRAS-mutant NSCLC
    Peter Sidaway
    Nature Reviews Clinical Oncology, 2021, 18 : 470 - 470
  • [5] A combinatorial strategy for treating KRAS-mutant lung cancer
    Eusebio Manchado
    Susann Weissmueller
    John P. Morris
    Chi-Chao Chen
    Ramona Wullenkord
    Amaia Lujambio
    Elisa de Stanchina
    John T. Poirier
    Justin F. Gainor
    Ryan B. Corcoran
    Jeffrey A. Engelman
    Charles M. Rudin
    Neal Rosen
    Scott W. Lowe
    Nature, 2016, 534 : 647 - 651
  • [6] A combinatorial strategy for treating KRAS-mutant lung cancer
    Manchado, Eusebio
    Weissmueller, Susann
    Morris, John P.
    Chen, Chi-Chao
    Wullenkord, Ramona
    Lujambio, Amaia
    de Stanchina, Elisa
    Poirier, John T.
    Gainor, Justin F.
    Corcoran, Ryan B.
    Engelman, Jeffrey A.
    Rudin, Charles M.
    Rosen, Neal
    Lowe, Scott W.
    NATURE, 2016, 534 (7609) : 647 - +
  • [7] Treating KRAS-Mutant Lung Cancer With Combination Agents
    Shumeyko, Emma P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 100 (04) : 315 - 315
  • [8] Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC
    Liu, Weiran
    Yin, Yuesong
    Wang, Jun
    Shi, Bowen
    Zhang, Lianmin
    Qian, Dong
    Li, Chenguang
    Zhang, Hua
    Wang, Shengguang
    Zhu, Jinfang
    Gao, Liuwei
    Zhang, Qiang
    Jia, Bin
    Hao, Ligang
    Wang, Changli
    Zhang, Bin
    ONCOTARGET, 2017, 8 (01) : 179 - 190
  • [9] Selumetinib in Advanced Non Small Cell Lung Cancer (NSCLC) Harbouring KRAS Mutation: Endless Clinical Challenge to KRAS-mutant NSCLC
    Maione, Paolo
    Sgambato, Assunta
    Rossi, Antonio
    Sacco, Paola Claudia
    Bareschino, Maria Anna
    Schettino, Clorinda
    Casaluce, Francesca
    Ciardiello, Fortunato
    Gridelli, Cesare
    REVIEWS ON RECENT CLINICAL TRIALS, 2013, 8 (02) : 93 - 100
  • [10] Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC
    Xia, Meng
    Li, Xuena
    Diao, Yao
    Du, Bulin
    Li, Yaming
    TRANSLATIONAL ONCOLOGY, 2021, 14 (01):
12345